Tivic Health's Net Loss Widens Amid Biopharma Pivot, Revenue Halves
Ticker: TIVC · Form: 10-Q · Filed: Nov 14, 2025 · CIK: 1787740
Sentiment: bearish
Topics: Biopharmaceutical, Going Concern, Net Loss, Revenue Decline, R&D Spending, Strategic Pivot, Reverse Stock Split
Related Tickers: TIVC
TL;DR
**TIVC is burning cash faster than ever on a risky biopharma pivot, making it a speculative bet with significant downside.**
AI Summary
Tivic Health Systems, Inc. (TIVC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $6.0 million, up from $4.2 million in the same period of 2024. Revenue declined sharply by 49.7% to $302,000 for the nine months ended September 30, 2025, compared to $600,000 in 2024, primarily due to the company's exit from its consumer healthtech business. Gross profit turned into a loss of $41,000 for the nine months ended September 30, 2025, a stark contrast to the $241,000 profit in 2024. Operating expenses surged by 33.1% to $5.9 million, driven by a 88.6% increase in research and development to $1.8 million and a 21.0% rise in general and administrative expenses to $3.0 million. The company's strategic shift into the biopharmaceutical market, marked by the acquisition of an exclusive license for Entolimod in February 2025, is a key business change. Cash and cash equivalents increased to $3.5 million as of September 30, 2025, from $2.0 million at December 31, 2024, largely due to $6.7 million in financing activities. However, the company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $49.6 million and negative cash flows from operations of $4.7 million for the nine months ended September 30, 2025.
Why It Matters
Tivic Health's pivot from consumer healthtech to biopharmaceuticals, highlighted by the Entolimod license, represents a high-stakes gamble for investors. While the company secured $6.7 million in financing, its rapidly expanding net loss and declining revenue from its legacy business signal significant operational challenges and a precarious financial position. This strategic shift places TIVC in direct competition with established biopharma players, demanding substantial R&D investment and successful clinical trials. For employees, this transition likely means a shift in skill sets and potential restructuring, while customers of its ClearUP device will see an exit from that market. The broader market will watch to see if TIVC can successfully navigate this complex and capital-intensive industry, or if its going concern risk materializes.
Risk Assessment
Risk Level: high — Tivic Health faces a high risk level, explicitly stating "substantial doubt about the Company's ability to continue as a going concern" due to a $6.0 million net loss and $4.7 million in negative cash flows from operations for the nine months ended September 30, 2025. The accumulated deficit of $49.6 million further underscores its precarious financial health, indicating a significant need for additional capital to fund its new biopharmaceutical strategy.
Analyst Insight
Investors should exercise extreme caution and consider TIVC a highly speculative investment. Given the explicit going concern warning and substantial cash burn, potential investors should wait for clear evidence of successful clinical trial progression for Entolimod and a solidified, sustainable financing plan before considering any position.
Financial Highlights
- debt To Equity
- 0.11
- revenue
- $302,000
- operating Margin
- N/A
- total Assets
- $6,229,000
- total Debt
- $638,000
- net Income
- -$6,000,000
- eps
- N/A
- gross Margin
- -13.6%
- cash Position
- $3,450,000
- revenue Growth
- -49.7%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Consumer Healthtech Business | $302,000 | -49.7% |
Key Numbers
- $6.0M — Net Loss (for the nine months ended September 30, 2025, up from $4.2M in 2024)
- $302K — Revenue (for the nine months ended September 30, 2025, down 49.7% from $600K in 2024)
- $49.6M — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
- $4.7M — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025, indicating cash burn)
- $3.5M — Cash and Cash Equivalents (as of September 30, 2025, an increase from $2.0M at December 31, 2024)
- $6.7M — Net Cash Provided by Financing Activities (for the nine months ended September 30, 2025, crucial for liquidity)
- $1.8M — Research and Development Expenses (for the nine months ended September 30, 2025, an 88.6% increase from 2024)
- 1-for-17 — Reverse Stock Split Ratio (effective March 7, 2025, impacting share count and price)
Key Players & Entities
- Tivic Health Systems, Inc. (company) — registrant of the 10-Q filing
- Statera Biopharma, Inc. (company) — licensor of Entolimod technology
- Entolimod (product) — late-stage toll-like receptor 5 agonist for Acute Radiation Syndrome
- Entolasta (product) — immune-optimized derivative of Entolimod
- ClearUP (product) — handheld device for sinus pain, business being exited
- SEC (regulator) — Securities and Exchange Commission
- Nasdaq Stock Market LLC (company) — exchange where TIVC common stock is registered
- Fremont, CA (location) — headquarters of Tivic Health Systems, Inc.
FAQ
What is Tivic Health Systems, Inc.'s current financial stability?
Tivic Health Systems, Inc. has significant financial instability, with an accumulated deficit of $49.6 million as of September 30, 2025, and a net loss of $6.0 million for the nine months ended September 30, 2025. The company explicitly states "substantial doubt about the Company's ability to continue as a going concern."
How has Tivic Health's revenue changed in 2025?
Tivic Health's revenue significantly declined by 49.7% to $302,000 for the nine months ended September 30, 2025, compared to $600,000 in the same period of 2024. This decrease is attributed to the company's ongoing exit from its consumer healthtech business.
What is Tivic Health's new strategic focus?
Tivic Health's new strategic focus is on becoming a late-stage prescription therapeutics company, harnessing the immune system. This pivot is evidenced by its acquisition of a worldwide exclusive license for Entolimod in February 2025 and an option for additional indications like neutropenia in March 2025.
What are the primary risks for Tivic Health investors?
The primary risks for Tivic Health investors include the substantial doubt about its ability to continue as a going concern, the need for significant additional financing to fund clinical trials and operations, and the inherent uncertainties of developing and obtaining regulatory approval for new biopharmaceutical products. The company's high cash burn from operations, totaling $4.7 million for the nine months ended September 30, 2025, also poses a significant risk.
How much cash does Tivic Health have on hand?
As of September 30, 2025, Tivic Health Systems, Inc. had $3.5 million in cash and cash equivalents. This is an increase from $2.0 million at December 31, 2024, primarily due to $6.7 million in financing activities during the nine-month period.
What was the impact of the reverse stock split on Tivic Health?
Effective March 7, 2025, Tivic Health implemented a 1-for-17 reverse stock split. This reduced the number of outstanding common shares and proportionally adjusted options, warrants, and convertible securities, aiming to increase the per-share trading price without changing the total par value or authorized shares.
What is Entolimod and why is it important to Tivic Health?
Entolimod is a late-stage toll-like receptor 5 agonist that Tivic Health acquired an exclusive worldwide license for in February 2025. It is important because it is central to the company's strategic pivot into the biopharmaceutical market, initially targeting Acute Radiation Syndrome (ARS) and later neutropenia.
How much did Tivic Health spend on research and development in 2025?
For the nine months ended September 30, 2025, Tivic Health spent $1.8 million on research and development. This represents an 88.6% increase compared to $980,000 spent in the same period of 2024, reflecting its new focus on biopharmaceutical product development.
What is the status of Tivic Health's ClearUP product line?
Tivic Health is in the process of exiting its ClearUP business, which is a handheld device for the treatment of sinus pain and congestion. This exit is part of its broader strategic shift away from consumer healthtech and into the biopharmaceutical market.
What regulatory body oversees Tivic Health's filings?
Tivic Health Systems, Inc.'s filings, including this 10-Q, are overseen by the Securities and Exchange Commission (SEC). The company is required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Risk Factors
- Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $49.6 million and negative operating cash flows of $4.7 million for the nine months ended September 30, 2025. This indicates a significant risk of financial distress.
- Increasing Net Loss and Operating Expenses [high — financial]: Net loss increased to $6.0 million for the nine months ended September 30, 2025, from $4.2 million in the prior year. Operating expenses surged 33.1% to $5.9 million, driven by substantial increases in R&D and G&A, exacerbating cash burn.
- Strategic Shift and Business Model Transition [medium — operational]: The company is undergoing a significant strategic shift from its consumer healthtech business to the biopharmaceutical market, involving the acquisition of an exclusive license for Entolimod. This transition carries inherent risks related to market acceptance, regulatory hurdles, and execution.
- Dependence on Financing Activities [medium — financial]: Cash and cash equivalents increased to $3.5 million as of September 30, 2025, primarily due to $6.7 million in financing activities. This highlights a heavy reliance on external funding to sustain operations, which may not be consistently available.
- Negative Gross Profit [medium — financial]: Gross profit turned into a loss of $41,000 for the nine months ended September 30, 2025, compared to a profit of $241,000 in the same period of 2024. This indicates a deterioration in the profitability of any remaining or new revenue-generating activities.
- Increased R&D Investment [medium — financial]: Research and development expenses increased by 88.6% to $1.8 million for the nine months ended September 30, 2025. While necessary for the biopharmaceutical strategy, this significant increase in spending further strains financial resources.
Industry Context
Tivic Health Systems is navigating a transition into the biopharmaceutical sector, a highly competitive and regulated industry characterized by long development cycles, significant R&D investment, and substantial clinical trial risks. The company's strategic shift towards licensing a specific drug candidate, Entolimod, places it in direct competition with established pharmaceutical companies and emerging biotech firms vying for market share and investor capital.
Regulatory Implications
The company's new focus on biopharmaceuticals means it will be subject to stringent regulatory oversight from bodies like the FDA. Successful development and commercialization of Entolimod will require navigating complex clinical trial pathways, manufacturing standards, and marketing approvals, all of which carry significant compliance burdens and timelines.
What Investors Should Do
- Monitor cash burn and financing needs closely.
- Evaluate the progress and potential of Entolimod.
- Assess the viability of the biopharmaceutical strategy.
- Consider the implications of the going concern warning.
Key Dates
- 2025-03-07: Reverse Stock Split — A 1-for-17 reverse stock split was effective, impacting share count and potentially share price, which is a common strategy for companies seeking to meet exchange listing requirements or improve market perception.
- 2025-02-01: Acquisition of Entolimod License — The company acquired an exclusive license for Entolimod, marking a significant strategic pivot into the biopharmaceutical market and shifting away from its previous consumer healthtech business.
- 2025-09-30: Quarter End Financial Reporting — Reporting period for the condensed financial statements, showing a net loss of $6.0 million and revenue of $302,000 for the nine months, alongside a cash balance of $3.5 million.
Glossary
- Accumulated Deficit
- The cumulative net losses of a company that have not been offset by net income or other gains. It represents the total historical losses since the company's inception. (Indicates significant historical unprofitability, with TIVC having an accumulated deficit of $49.6 million as of September 30, 2025.)
- Going Concern
- An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (TIVC faces substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)
- Licensed Technology
- Refers to intellectual property or technology that a company has obtained the right to use from another party, often through a licensing agreement. (TIVC recorded $2.2 million in 'Licensed technology' as of September 30, 2025, reflecting the acquisition of the Entolimod license.)
- Reverse Stock Split
- A corporate action in which a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (TIVC executed a 1-for-17 reverse stock split effective March 7, 2025, impacting its share structure.)
- Additional Paid in Capital
- The amount of money a company receives from selling stock above its par value. It represents capital contributed by shareholders beyond the nominal value of the stock. (TIVC's Additional Paid in Capital increased to $55.2 million as of September 30, 2025, reflecting capital raised through stock issuances.)
Year-Over-Year Comparison
Compared to the prior year, Tivic Health Systems has experienced a significant revenue decline of 49.7% for the nine months ended September 30, 2025, reflecting its strategic exit from the consumer healthtech business. This revenue drop, coupled with a substantial increase in operating expenses (33.1%) driven by R&D and G&A, has led to a widening net loss. While cash has increased due to financing activities, the company's gross profit has turned negative, and it faces heightened going concern risks, indicating a challenging financial trajectory despite the strategic pivot.
Filing Stats: 4,687 words · 19 min read · ~16 pages · Grade level 17.4 · Accepted 2025-11-14 16:34:12
Key Financial Figures
- $0.0001 — of Each Class Common Stock, par value $0.0001 per share Trading Symbol(s) TIVC
Filing Documents
- tivc20250930_10q.htm (10-Q) — 1625KB
- ex_859899.htm (EX-31.1) — 13KB
- ex_859900.htm (EX-31.2) — 13KB
- ex_859901.htm (EX-32.1) — 8KB
- tivc20250930_10qimg001.jpg (GRAPHIC) — 3KB
- 0001437749-25-035216.txt ( ) — 8647KB
- tivc-20250930.xsd (EX-101.SCH) — 87KB
- tivc-20250930_cal.xml (EX-101.CAL) — 38KB
- tivc-20250930_def.xml (EX-101.DEF) — 532KB
- tivc-20250930_lab.xml (EX-101.LAB) — 478KB
- tivc-20250930_pre.xml (EX-101.PRE) — 571KB
- tivc20250930_10q_htm.xml (XML) — 1438KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION Page Item 1.
Financial Statements
Financial Statements 1 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 42 Item 4.
Controls and Procedures
Controls and Procedures 42
- OTHER INFORMATION
PART II - OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 44 Item 1A.
Risk Factors
Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45
Signatures
Signatures 46 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Our condensed financial statements included in this Quarterly Report on Form 10Q are as follows: Condensed Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 2 Condensed Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (unaudited) 3 Condensed Statements of Stockholders ' Equity for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Condensed Statements of Cash Flow for the nine months ended September 30, 2025 and 2024 (unaudited) 6 Notes to Condensed Financial Statements (unaudited) 7 This Quarterly Report on Form 10Q (this "Quarterly Report") for the quarter ended September 30, 2025, should be read in conjunction with the Tivic Health Systems, Inc.'s Annual Report on Form 10K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 21, 2025. The accompanying condensed financial statements and footnotes have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2025 are not necessarily indicative of the results that can be expected for the full year. 1 Table of Contents Tivic Health Systems, Inc. Condensed Balance Sheets September 30, 2025 and December 31, 2024 (in thousands, except share and per share data) September 30, December 31, 2025 2024 (Unaudited) (Audited) ASSETS Current assets Cash and cash equivalents $ 3,450 $ 2,002 Accounts receivable, net 19 69 Inventory, net 4 319 Prepaid expenses and other current assets 267 249 Total current assets 3,740 2,639 Property and equipment, net 12 119 Deferred offering costs 211 49 Licensed techn